Detoxifying enzymes (XMEs)

Detoxifying enzymes, scientifically referred to as xenobiotic-metabolizing enzymes (XMEs), represent a broad and diverse class of proteins responsible for the biotransformation of foreign compounds such as drugs, environmental pollutants, and endogenous toxins [1]. These enzymes are classically divided into Phase I (functionalization) enzymes, like the Cytochrome P450 (CYP) family, which introduce reactive groups, and Phase II (conjugation) enzymes, such as Glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases (UGTs), which increase water solubility for excretion [2][5]. Their primary biological role is to protect the organism from chemical insult, though they can occasionally activate inert compounds into highly reactive, toxic intermediates [3]. In pharmacology, these enzymes are critical determinants of a drug's half-life and efficacy, and they are frequent sites of drug-drug interactions when one substance induces or inhibits the metabolism of another [4]. Furthermore, therapeutic strategies often focus on inducing these enzymes, particularly through the Nrf2 signaling pathway, to enhance cellular defense against oxidative stress and prevent carcinogenesis [6].

Other names

Xenobiotic-metabolizing enzymesBiotransformation enzymesPhase I and Phase II enzymesDrug-metabolizing enzymes

Drugs typically interact with these enzymes through induction (increasing enzyme expression via transcription factors like Nrf2, PXR, or CAR) or inhibition (binding to the enzyme to decrease its catalytic activity), thereby modulating the metabolic clearance and toxicity profiles of various compounds [1][3].